Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

835

Participants

Timeline

Start Date

February 22, 2022

Primary Completion Date

January 10, 2023

Study Completion Date

January 10, 2023

Conditions
Pneumococcal Vaccines
Interventions
BIOLOGICAL

24 valent pneumococcal conjugate vaccine

0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1

BIOLOGICAL

20 valent pneumococcal conjugate vaccine

0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1

Trial Locations (13)

14609

Rochester Clinical Research, Rochester

28401

Acellacare of Wilmington, Wilmington

29405

Coastal Carolina Research, North Charleston

31406

Meridian Clinical Research, Savannah

33024

CenExel RCA, Hollywood

33351

Precision Clinical Research, Sunrise

46383

Velocity Clinical Research, Valparaiso

64114

Alliance for Multispecialty Research, Kansas City

66219

Johnson County Clin-Trials, Lenexa

70006

Benchmark Research, Metairie

76904

Benchmark Research, San Angelo

84107

JBR Clinical Research, Salt Lake City

02886

Velocity Clinical Research, Warwick

All Listed Sponsors
lead

Vaxcyte, Inc.

INDUSTRY